Tonix Pharmaceuticals (NASDAQ:TNXP) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXPGet Rating) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the stock.

Separately, Noble Financial initiated coverage on shares of Tonix Pharmaceuticals in a research note on Monday, April 18th. They issued an “outperform” rating and a $0.60 price target on the stock.

TNXP stock opened at $0.15 on Wednesday. The business’s 50-day moving average price is $0.21 and its 200-day moving average price is $0.34. Tonix Pharmaceuticals has a twelve month low of $0.15 and a twelve month high of $1.42. The stock has a market cap of $81.21 million, a P/E ratio of -0.59 and a beta of 1.29.

Tonix Pharmaceuticals (NASDAQ:TNXPGet Rating) last released its quarterly earnings data on Monday, March 14th. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.07). As a group, equities analysts forecast that Tonix Pharmaceuticals will post -0.2 earnings per share for the current year.

Hedge funds have recently modified their holdings of the company. Royal Bank of Canada bought a new stake in shares of Tonix Pharmaceuticals in the second quarter worth about $25,000. Citigroup Inc. increased its holdings in shares of Tonix Pharmaceuticals by 197.3% in the third quarter. Citigroup Inc. now owns 46,217 shares of the company’s stock worth $28,000 after purchasing an additional 30,669 shares during the last quarter. Two Sigma Advisers LP bought a new stake in shares of Tonix Pharmaceuticals in the third quarter worth about $37,000. Susquehanna International Group LLP bought a new stake in shares of Tonix Pharmaceuticals in the fourth quarter worth about $45,000. Finally, Jane Street Group LLC increased its stake in Tonix Pharmaceuticals by 558.9% during the third quarter. Jane Street Group LLC now owns 79,091 shares of the company’s stock worth $48,000 after acquiring an additional 67,088 shares during the last quarter. 17.46% of the stock is currently owned by hedge funds and other institutional investors.

About Tonix Pharmaceuticals (Get Rating)

Tonix Pharmaceuticals Holding Corp. discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include biologics to address organ transplant rejection, autoimmune diseases, and cancer; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions.

Featured Articles

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.